Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) EPS (Basic) (2023 - 2025)

Historic EPS (Basic) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to -$0.33.

  • Monte Rosa Therapeutics' EPS (Basic) fell 1379.31% to -$0.33 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.32, marking a year-over-year increase of 11758.24%. This contributed to the annual value of -$0.98 for FY2024, which is 6258.42% up from last year.
  • As of Q3 2025, Monte Rosa Therapeutics' EPS (Basic) stood at -$0.33, which was down 1379.31% from -$0.15 recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' EPS (Basic) ranged from a high of $0.57 in Q1 2025 and a low of -$0.71 during Q2 2023
  • Its 3-year average for EPS (Basic) is -$0.33, with a median of -$0.43 in 2024.
  • The largest annual percentage gain for Monte Rosa Therapeutics' EPS (Basic) in the last 5 years was 20754.72% (2025), contrasted with its biggest fall of 1379.31% (2025).
  • Monte Rosa Therapeutics' EPS (Basic) (Quarter) stood at -$0.57 in 2023, then soared by 131.82% to $0.18 in 2024, then tumbled by 281.92% to -$0.33 in 2025.
  • Its EPS (Basic) was -$0.33 in Q3 2025, compared to -$0.15 in Q2 2025 and $0.57 in Q1 2025.